Here's What Key Metrics Tell Us About Phreesia (PHR) Q1 Earnings

Phreesia (PHR) reported $115.94 million in revenue for the quarter ended April 2025, representing a year-over-year increase of 14.5%. EPS of -$0.07 for the same period compares to -$0.35 a year ago.

The reported revenue represents a surprise of +1.09% over the Zacks Consensus Estimate of $114.69 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +46.15%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Phreesia performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Average healthcare services Clients: 4,411 compared to the 4,373 average estimate based on three analysts.
• Patient payment volume: $1.31 billion compared to the $1.25 billion average estimate based on three analysts.
• Payment facilitator volume percentage: 82% versus 81.3% estimated by two analysts on average.
• Revenus- Subscription and related services: $54.36 million versus $52.43 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +16.3% change.
• Revenus- Network solutions: $31.66 million versus the six-analyst average estimate of $33.40 million. The reported number represents a year-over-year change of +15.5%.
• Revenus- Payment processing fees: $29.93 million compared to the $28.87 million average estimate based on six analysts. The reported number represents a change of +10.6% year over year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research